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ABSTRACT
Oral squamous cell carcinoma (OSCC) is an aggressive malignancy with high 
mortality rates. Major challenges for OSCC management include development of 
resistance to therapy and early formation of distant metastases. Cancer stem cells 
(CSCs) have emerged as important players in both pathologic mechanisms. Increased 
fucosylation activity and increased expression of fucosylated polysaccharides, such 
as Sialyl Lewis X (SLex), are associated with invasion and metastasis. However, 
the role of fucosylation in CSCs has not been elucidated yet. We used the spheroid 
culture technique to obtain a CSC-enriched population and compared orospheres with 
adherent cells. We found that orospheres expressed markers of CSCs and metastasis 
at higher levels, were more invasive and tumorigenic, and were more resistant to 
cisplatin/radiation than adherent counterparts. We found fucosyltransferases FUT3 
and FUT6 highly up-regulated, increased SLex expression and increased adhesion 
by shear flow assays in orospheres. Inhibition of fucosylation negatively affected 
orospheres formation and invasion of oral CSCs. These results confirm that orospheres 
are enriched in CSCs and that fucosylation is of paramount importance for CSC 
invasion. In addition, SLex may play a key role in CSC metastasis. Thus, inhibition of 
fucosylation may be used to block CSCs and metastatic spread.
INTRODUCTION
Head and neck (H&N) squamous cell carcinoma 
(HNSCC) is one of the world’s top ten most common 
cancers: in fact, it is ranked the 8th and 13th most common 
malignancy, respectively, for males and females [1-3]. 
Unfortunately, current treatments for HNSCC can be 
traumatic and disfiguring, drastically affecting quality 
of life [4, 5]. Management of HNSCC includes surgical 
resection and/or a combination of chemo- and radio-
therapy [1, 6]. Despite these treatments, the prognosis of 
HNSCC remains poor due to late diagnosis, high rates of 
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primary-site recurrence, and common metastases to loco-
regional lymph nodes [2, 6, 7].
Oral squamous cell carcinoma (OSCC), which 
includes epithelial neoplasms of the oral cavity and 
oropharynx, accounts for the majority of HNSCCs [8] 
and causes cancer-related mortality with an estimated 
>275,000 new cases and >120,000 deaths per year 
[9]. Despite the numerous advances in diagnosis and 
treatment of oral cancer, mortality and morbidity rates 
for OSCC are exceedingly high: the five-year survival 
rate of stage I cancer including the various sub-sites, such 
as borders of the tongue, floor of the mouth, cheek, and 
gums, is approximately 80%, while the five-year survival 
rate of patients with advanced disease (stages III/IV) is 
approximately 20%. Worldwide, about 50% of OSCC 
patients are diagnosed with advanced disease and the 
available treatment modalities are still limited. Therefore, 
novel treatment options and diagnostic tools are needed to 
improve disease outcome.
Cancer stem cells (CSCs) are a small subpopulation 
of self-sustaining cancer cells with the ability to form 
the heterogeneous cell lineages that compose the tumor 
[10]. CSCs are characterized by three main features: 
i) potent tumor initiation; ii) self-renewal in vivo 
(observed practically via re-growth of phenotypically 
indistinguishable tumors following serial transplantation 
of re-isolated CSCs in secondary and tertiary recipients); 
and iii) cell differentiation capacity, allowing them to give 
rise to a heterogeneous progeny representing a phenocopy 
of the original tumor [11]. CSCs have been proposed to be 
responsible for the aggressive behavior of several cancer 
types via the appropriation of the molecular machinery of 
homing and mobilization involved in tumor invasion and 
metastasis [12].
There are many methodologies to detect, isolate, 
and characterize CSCs from tumors: the main methods 
are cell sorting based on stemness marker expression, side 
population profiling, and formation of floating spheres [13-
15]. Sphere formation in vitro allows selection of CSC-
rich populations, and this method is particularly useful 
when specific CSC makers have not been well defined, 
as is the case for most cancer types [16]. CSCs have been 
identified in many solid tumors, including breast [17], lung 
[18], colon [19], prostate [20], ovary [21], brain cancer 
[22], and sarcoma [23]; in H&N cancer, the existence of 
CSCs was first assessed using CD44 as a stem cell marker 
[24].
Fucosyltransferases (FUTs) are a family of Golgi-
apparatus enzymes that transfer L-fucose from GDP-
fucose to a glycoside or a peptide. According to the 
fucosylation site, FUTs are classified into alpha-1,2 
(FUT1 and FUT2), alpha-1,3/4 (FUT3, FUT4, FUT5, 
FUT6, FUT7, and FUT9), and alpha-1,6 (FUT8) [25]. 
In mammals, fucosylated glycans are involved in cell 
adhesion during development [26, 27], the inflammatory 
response, and leukocyte trafficking [28, 29]. Great 
attention has been paid to FUTs and their inhibitors over 
the past 20 years due to the fact that addition of L-fucose 
is involved in a series of diseases, including cancer and 
metastatic spread [30-33]. Sialyl Lewis X (SLex) is a 
cell-surface tetrasaccharide carbohydrate involved in 
many recognition processes. It is synthesized in the 
Golgi compartment by different glycosyltransferases, 
with the final step involving the transfer of L-fucose to 
N-acetylglucosamine by alpha-1,3-FUT3/5/6/7, depending 
on the cell type [34].
In this study, we extensively compared orospheres 
with their adherent cell counterpart in terms of gene 
expression, stem cell and metastasis marker profile, 
cell adhesion and invasion, potential to form tumors in 
an animal model, and resistance to drugs and radiation. 
Moreover, we show that inhibition of fucosylation affects 
the orosphere formation and invasion ability of CSCs.
RESULTS
Orospheres formation
The ability to grow in suspension in serum-free 
medium was investigated with a tumor-initiating cell-
selection method. OSCC orospheres were clearly observed 
already after 24 h in serum-free medium. After 7 days of 
culture, orospheres were seeded onto standard plates with 
10% FBS. Cells migrated from the spheres within a few 
hours and adhered to the bottom of the flasks, assuming 
their original shape.
Orospheres have protein and RNA expression 
typical of CSCs and increased propensity to grow 
in vivo
Orospheres and corresponding adherent cells of 
two OSCC lines (UMSCC14B and UMSCC103) were 
assessed for expression of CD44, CD29, CD56, sialyl 
LewisX (SLeX), sialyl Lewis A (SLa) and Lewis Y (Ly) 
as well as for aldehyde dehydrogenase (ALDH) activity. 
CD44 and ALDH activity are the most common markers 
of CSCs in OSCC [24, 35]; CD29 is a β1-integrin involved 
in invasion and metastasis that has been used as a CSC 
marker for different cancers [36]; and CD56 (N-CAM), 
which we describe here for the first time in oral cancer, 
has been correlated with invasion and distant metastasis 
in many cancers [37-39].
Cytometric analyses revealed that orospheres were 
remarkably more positive for ALDH activity than their 
adherent counterpart. In UMSCC14B cells, CD44 was 
more expressed on orospheres, while in the UMSCC103 
cell line CD44 was more expressed by adherent cells. 
Nevertheless, in both cell lines, CD44–ALDH double-
positivity was remarkably higher in orospheres than 
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corresponding adherent cells (Fig. 1A).
Similarly, CD29, CD56, and SLex were consistently 
higher on orospheres than adherent cells (Fig1B). SLa 
was highly expressed by UMSCC14B but only slightly 
expressed by UMSCC103 cell lines. No variations were 
observed between orospheres and adherent cells in both 
cases. Ly had a different pattern, being more expressed 
by orospheres in the UMSCC14B cell line, but more 
expressed by adherent cells in the UMSCC103 cell line. 
Neither SLa nor Ly seemed to be associated with the 
orospheres culture condition (Fig. 1B).
RNA from orospheres and adherent cells from 
both cell lines was extracted and PCR performed for 
genes related to stemness and metastasis. ALDH RNA 
expression was higher in orospheres of both cells lines, 
showing that orospheres not only have higher enzyme 
activity but that they also produce more ALDH. N-CAM 
RNA expression levels were also consistently higher in 
orospheres (Supplementary Table 1), as assessed by the 
cytometric analysis. Furthermore, the RNAs of VEGF, 
Figure 1: Cancer stem cell characterization. A. Flow cytometry analysis of CD44 and ALDH activity. The CD44+/ALDH+ 
subpopulation is larger in orospheres in both UMSCC14B and UMSCC103 cell lines. B. Summary of marker expression in orospheres 
and adherent cells. *P<0.05 C. Real time PCR for the most common stem cell-related markers (OCT3/4, SOX-2, NANOG). All stem 
cell-related markers are remarkably more expressed on orospheres. *P<0.05. D. Growth curve of orospheres and adherent cells implanted 
in immunocompromised mice. In both cell lines, the orospheres show faster growth, resulting in larger tumors at the time of sacrifice. 
E. Examples of explanted tumors for both cell lines. Orospheres produce remarkably larger tumors. Scale bar=4mm. F. H&E staining 
on sections of explanted and original primary tumors. Orospheres and adherent cells recapitulate the architecture of the original tumor. 
Original magnification: 100X (xenograft); 400X (original primary tumor).
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CXCR2, MMP10, PAR6, and FXYD5 (dysadherin), 
well-known markers associated with metastasis and poor 
prognosis in different cancers, including OSSC [40-43], 
were all up-regulated in orospheres (Supplementary Table 
1), as were the RNAs of commonly recognized markers of 
normal stem cells and CSCs, such as SOX-2, OCT3/4, and 
NANOG (Fig. 1C).
To evaluate tumorigenic potential, orospheres and 
adherent cells were injected into the flanks of NOD/SCID 
immunodeficient mice. Tumor growth was measured 
every three days after tumors were first detected. 24-27 
days after implantation, both orospheres and adherent cells 
were found to generate tumors in all cases, but although 
the same number of cells were injected, tumor size and 
growth of orospheres was significantly greater than that 
of adherent cells (p<0.05) (Fig. 1D and 1E). Hematoxylin 
and eosin staining revealed that the xerographs 
reconstituted the characteristics of the original primary 
tumor architecture (Fig. 1F).
Orospheres are resistant to Cisplatin and 
radiation treatment
We performed a preliminarily dose-response 
evaluation of the growth inhibition induced by either 
cisplatin or radiation on adherent cell lines after 24h 
of treatment (Supplementary Figure 1). On the basis of 
the results, we used for all the subsequent experiments 
the concentrations that caused at least 20% cell death. 
Therefore, the cell lines were treated with 80µM cisplatin 
and cell death analyzed after 24 hours. In both cell lines, 
orospheres had greater resistance to cisplatin-induced 
death than the corresponding adherent cells (Fig. 2A and 
Supplementary Table 2). In particular, the UMSCC103 
cell line had higher sensitivity to cisplatin treatment, 
both as orospheres and adherent cells. In addition, IC50 
was calculated from the dose-response curve assessed 
with a MTT assay (Fig.2B). For both cell lines, IC50 of 
orospheres was significantly higher than for adherent cells. 
Figure 2: Cisplatin and radiation resistance. A. Graphs of non-viable (apoptotic+necrotic) cells measured by Annexin V/PI staining 
after cisplatin (after 24 hours) or radiation (after 48 hours) treatment. Orospheres are more resistant to both treatments. *P<0.05. B. Dose-
response curves for IC50 calculation (UMSCC14B adherent cells, 114 (95% CI 104-126); UMSCC14B orospheres, 144 (95% CI 134-155); 
UMSCC103 adherent cells, 26.5 (95% CI 18-39); UMSCC103 orospheres, 58 (95% CI 47-72). C. Colony formation was measured 15 days 
after cisplatin or radiation treatment. Orospheres form significantly more colonies than adherent cells. *P<0.05. 
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IC50 values were: 114 (95% CI 104-126) for UMSCC14B 
adherent cells, 144 (95% CI 134-155) for UMSCC14B 
orospheres, 26.5 (95% CI 18-39) for UMSCC103 adherent 
cells, and 58 (95% CI 47-72) for UMSCC103 orospheres.
We also assessed radiation resistance. Even for 
this death stimulus, orospheres were more resistant than 
corresponding adherent cells (Fig. 2A). In both cell lines, a 
slight increase of necrosis was also found (Supplementary 
Fig. 2 and table 2). The findings were confirmed by colony 
forming assay (Fig. 2C and Supplementary Table 2): while 
adherent cells formed no or few colonies, orospheres were 
consistently able to form visible colonies.
Orospheres are more invasive and show increased 
fucosylation
The invasive ability of cells was then assessed with 
a Matrigel invasion chamber assay. Orospheres derived 
from the cell lines were significantly more invasive than 
Figure 3: Fucosylation and SLex expression - functional assays. A. Invasion assay of orospheres vs adherent cells. Orospheres 
are significantly more invasive than adherent cells. B. Quantitative mRNA expression of FUTs. In both cell lines, FUT5 and FUT7 are 
not expressed, while FUT3 and FUT6 are more expressed in orospheres. C. Sialyl Lewis X (SLex) expression on orospheres and adherent 
cells (flow cytometry). Orospheres express a higher level of SLex as compared with their adherent counterparts (UMSCC14B: 93% for 
orospheres vs 27.2 for adherent cells; UMSCC103: 97% for orospheres vs 93% for adherent cells). Moreover, the mean fluorescence 
intensity for UMSCC103 is much higher than that of adherent cells, with most of the cells after the 4th decade of fluorescence intensity. D. 
qPCR for FUT 3/6 expression on SLex sorted cells. SLex+ cells have significantly increased FUTs expression. E. Invasion assay for SLex+ vs 
SLex−. SLex+ cells are significantly more invasive than SLex− cells. F. Shear flow assay. Graphs of percentages of firmly adherent (sticking) 
and rolling cells. The rate of firmly adherent (sticking) cells is higher for orospheres in both cell lines, while there is no significant difference 
in rolling cells. Moreover, the mean velocity of rolling cells is much lower for orosphere-derived cells than for adherent cells. *P<0.05. 
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adherent cells: UMSCC14B orospheres-derived cells had 
a 2.4-fold increase, while those derived from UMSCC103 
orospheres had a 1.75-fold increased ability to migrate 
(Fig. 3A). Moreover, expression of FUT3 and FUT6 
mRNA was significantly higher in orospheres (Fig. 3B), 
but FUT5 and FUT7 were not expressed in either adherent 
cells or orospheres (Fig. 3B). In addition, orospheres of 
both cell lines had a strong increase in the fucosylated 
carbohydrate SLex (Fig 3C). In order to further investigate 
a possible relation between FUT and SLex expression, 
we sorted cells for surface SLex, extracted the RNA, and 
performed qPCR for FUTs 3/6 expression. In both cell 
lines, the SLex+ subpopulation had a significantly higher 
expression of FUTs (Fig 3D). Consequently, we found that 
SLex+ cells had a significantly greater invasive ability than 
SLex- cells. (Fig. 3E). 
Shear flow is a functional analysis assessing the 
ability of cells to roll and stick on E-selectin-expressing 
endothelium. Rolling and adhesion to E-selectin 
-expressing endothelial cells is a key step for metastasis 
initiation. Orospheres-derived cells showed a significantly 
greater ability to adhere to E-selectin-expressing CHO 
cells than did adherent cells (Fig. 3F). In UMSCC14B 
and UMSCC103 cells, adhesion of orosphere-derived 
cells was respectively 2-fold and 3.58-fold greater than 
their adherent counterpart. Rolling was not significantly 
different in the former; in the latter, orospheres rolled at 
slightly lower percentages than adherent cells, but the 
difference was not significant (Fig. 3F).
Of note, the maximum velocity calculated for 
UMSCC103 orospheres-derived cells (31.83 μm/s) 
was about half that of the adherent cells (60.82 μm/s), 
indicating that orospheres cells are more adherent to 
the monolayer. This correlation was found also for the 
UMSCC14B cell line. 
FUT inhibition reduces orospheres formation
In order to evaluate the effect of fucosylation on 
orospheres formation, we incubated adherent cells with the 
specific inhibitor 2F-peracetyl-fucose for 72 hours prior 
to detaching the cells for orospheres formation. Inhibition 
of fucosylation with 2F-peracetyl-fucose resulted in the 
formation of fewer and smaller orospheres formation (Fig. 
4A and B). Moreover, treatment significantly reduced 
invasion ability of orospheres (Fig. 4C): UMSCC14B cells 
had a 1.49-fold decrease, while UMSCC103 cells had a 
1.7-fold decrease after treatment. 
DISCUSSION
Prince el al. first described CSCs in H&N cancer as 
a subpopulation of CD44+/CD24-/low cells [24]. Later, Clay 
et al. used ALDH1 activity to additionally characterize the 
stem-like subpopulation in H&N cancers [35]. Recently, 
floating spheres have also been used to elucidate the roles 
of CSCs in H&N cancer [44, 45].
To date, there is no available therapy targeting CSCs 
directly. A detailed characterization of CSCs and the 
discovery of new mechanisms involved in the metastatic 
process, stem-like feature acquisition, and drug resistance 
is necessary for the identification of more-effective 
strategies against this aggressive and resistant subset of 
cells. Increased fucosylation has been associated with 
metastatic and invasive properties of cancer cells [46-48]; 
moreover, inhibition of fucosylation has been successfully 
used against tumor growth and metastasis in vitro and in 
vivo [49, 50]. In this light, our aim was to understand 
the role of fucosylation in CSCs-mediated invasion and 
metastasis in OSCC.
We firstly characterized H&N-derived CSCs in 
terms of marker expression, tumorigenic potential, and 
metastatic and invasive ability. Both cell lines studied 
were able to grow as orospheres that could be passaged 
Figure 4: FUT inhibition. A. Orosphere size in cells treated with 2F-peracetyl-fucose. Treated cells of both lines produced significantly 
smaller sized orospheres. B. Image of orospheres from 2F-peracetyl-fucose-treated and -untreated cells. C. Invasion assay of orospheres 
treated and untreated with 2F-peracetyl-fucose. Treated cells had significantly reduced invasion ability.
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for at least three times. Orospheres and adherent cells were 
analyzed comparatively for expression of several markers, 
including ALDH activity and CD44. It is generally 
accepted that ALDH activity and CD44 expression are 
reliable markers for CSC identification in carcinomas 
from the head and neck areas [24, 35, 51]. In our study, 
orospheres from both cell lines had increased ALDH 
activity compared with adherent counterparts. On the 
other hand, CD44 expression was higher in UMSCC14B 
orospheres than in adherent cells, differently to the 
UMSCC103 cell line, in which CD44 was more expressed 
on adherent cells. Nevertheless, the percentage of double-
positive cells for ALDH activity and CD44 expression was 
higher in orospheres than in adherent cells for UMSCC14B 
and UMSCC103 cell lines. Previous studies suggested that 
CD44 is also highly expressed in normal oral epithelium, 
similar to the expression detected in OSCC [52], while 
various CD44 variant isoforms that arise from alternative 
exon splicing are exclusively expressed in tumors, where 
they were significantly associated with advanced primary 
tumor stage, metastasis, treatment failure, and reduced 
disease-free survival [53, 54]. For these reasons, CD44 
should be used in combination with other markers for the 
reliable identification of CSCs.
Furthermore, orospheres had a pattern of gene 
expression typical of stem cells, characterized by up-
regulation of genes such as OCT4, NANOG, and SOX2. 
These findings were reinforced by up-regulation of other 
genes related not only to stemness but also to tumor 
progression and negative outcome, including NCAM 
and PAR-6 [42]. Interestingly, to our knowledge, CD56 
(NCAM) has not been described before in OSCC-derived 
CSCs. NCAM is an homophilic binding glycoprotein 
expressed on the surface of various cells (e.g. neurons, 
glia, skeletal muscle, and natural killer cells), which 
has been correlated to invasion and distant metastasis in 
many human cancers, including small cell lung cancer, 
thyroid cancer, hepatocellular carcinomas, and glioma 
[37-39]. In order to better understand the potential links 
between CSCs and metastasis formation, we performed 
PCR arrays for genes related to metastasis. We found that 
orospheres overexpressed several genes, such as VEGF, 
FXYD5 (dysadherin), CXCR2, and MMP10, that have been 
strongly correlated with invasion and metastasis in many 
cancers, including H&N carcinomas [40, 41, 43].
Two of the most important characteristics of CSCs 
are the ability to generate tumors in immunocompromised 
mice [19, 44] and resistance to conventional therapy [44, 
55]. Here, we have demonstrated that tumors originating 
from orospheres grow faster and bigger than those 
originating from adherent cells, confirming the capacity of 
orospheres to initiate and sustain tumor growth. Moreover, 
cells derived from orospheres were significantly more 
resistant to cisplatin and radiation treatment than adherent 
cells. These results strongly suggest that orospheres 
are enriched in CSCs and that they represent a highly 
reproducible model for studying CSCs in OSCC.
Sialyl Lewis X is an E-selectin ligand with a 
carbohydrate structure that is constitutively expressed 
on granulocytes and monocytes, mediating inflammatory 
extravasation of these cells [56]. We found that SLex 
expression was strongly associated with orospheres, 
confirming our recent preliminary report [57]. In 
different cancers, SLex expression has been related to 
poor prognosis and metastasis, suggesting that it may be 
involved in cancer cell extravasation [58-61]. Consistently, 
we found increased expression of FUT3 and FUT6 
(involved in SLex synthesis) in orospheres concurrently 
to increased levels of SLex. In our model, other FUT3/6 
products, such as SLa and Sly, were not associated with 
the orosphere culture condition. The expression pattern 
of these two Lewis family saccharides is discordant with 
the increase in FUT3/6 that we found in orospheres, 
suggesting that other enzymes may be responsible for 
their regulation. At the same time, sorted SLex+ adherent 
cells expressed significantly higher levels of FUT3/6 than 
did SLex- cells. In addition a causal correlation between 
FUT3/6 and SLex levels has been showed in other 
models[34, 62-65]
Taken together, these findings strongly suggest 
that increased expression of FUT3/6 is associated with 
increased SLex production. An invasion assay indicated 
that SLex+ cells (with high FUTs expression) levels 
were significantly more invasive than SLex- cells (with 
low FUTs), suggestive of an association between FUTs 
expression and invasive phenotype.
Moreover, shear flow assays, mimicking the 
potential interaction between tumor cells and endothelium, 
showed that orospheres are remarkably more able to 
adhere to E-selectin-expressing cell layer, a feature that is 
of paramount importance for distant metastasis formation 
[60, 66]. We did not find a significant difference in the 
number of rolling cells, but we did find a consistent and 
substantial difference in firmly adherent cell number and 
in the mean velocity of rolling cells. Thus, orospheres-
derived CSCs have greater ability to bind to E-selectin. 
SLex is the main E-selectin ligand, and we found it 
to be overexpressed on orospheres-derived cells with 
increased FUT3/6 expression. 2F-peracetyl-fucose is the 
only commercially available inhibitor of fucosylation 
[67]. We show that inhibition of fucosylation negatively 
affects orospheres formation, producing smaller-sized 
spheroids. Sphere formation is widely used to enrich the 
CSC population, and is recognized as a standard tool 
to assess and confirm self-renewal in stem-like cells. 
Interestingly, inhibition of fucosylation also affected 
invasion ability of sphere-derived CSCs. Even though in 
vitro migration assays are not comprehensive methods for 
broad characterization of the invasive process, they have 
been extensively used and correlated to cancer invasion 
in vivo [63, 64]. Moreover, inhibition of fucosylation 
affects E-selectin binding and cell extravasation [49], 
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and Cheng et al. [68] showed that FUT family members, 
including FUT6, are involved in multidrug resistance in 
hepatocellular carcinomas. Based on this previous data 
and on the findings of this study, we hypothesize that 
increased fucosylation may be a mechanism used by CSCs 
to acquire not only invasive and metastatic features, but 
also resistance to conventional therapy.
CONCLUSIONS
Our study demonstrates the following: (i) orospheres 
are enriched in CSCs, express higher levels of metastatic 
markers, and are more tumorigenic than adherent 
counterparts; and (ii) fucosylation is of paramount 
importance in the invasion and metastatic process of 
CSCs. Among fucosylated saccharides, Sialyl Lewis X is 
a strong candidate in the acquisition of a FUT-associated 
invasive phenotype. Thus, inhibition of fucosylation may 
represent an active therapeutic tool against cancer stem 
cells and metastatic spreading. 
METHODS 
Ethics Statement
The investigation was conducted in accordance with 
the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Cell culture and orospheres formation
OSCC cell lines (UMSCC14B, UMSCC103), 
used in this study were established at the University of 
Michigan under a protocol approved by the Institutional 
Review Board Office in accordance with the university’s 
regulations [69, 70]. Cells were cultured in DMEM 
(Gibco, NY, USA) supplemented with 2 mM glutamine, 
100 IU/ml penicillin, 100 μg/ml streptomycin (Invitrogen, 
Carlsbad, CA), and 10% heat-inactivated fetal bovine 
serum (FBS) (Invitrogen Life Technologies, NY, USA) 
at 37°C in a humidified atmosphere under 5% CO2. Cells 
were passaged at a split ratio of 1:3–1:6. The cell lines 
used in this study were negative in periodic monitoring 
for mycoplasma. The cell lines were also genotyped to 
rule out cross-contamination and their morphology was 
regularly examined.
For orosphere formation, cells were plated at a 
density of 3 × 105 cells in 25 cm2 ultra-low-attachment 
flasks (Corning, NY, USA) in DMEM/F12 supplemented 
with B27 and N2 supplement (Gibco, NY, USA), 100 IU/
ml penicillin, and 100 μg/ml streptomycin (Invitrogen, 
Carlsbad, CA). Human fibroblast growth factor (FGF, 
20ng/ml) and epidermal growth factor (EGF, 20ng/
ml) (both from Sigma Aldrich, MO, USA) were added 
every other day. After 48–72 hours, orospheres were 
enzymatically dissociated and re-cultured in the same 
condition to form second- and then third-passage 
orospheres, which were used for experiments. Inhibition of 
fucosylation was obtained as described by Rillahan et al. 
[67] using the fucosyltransferase inhibitor 2F-Peracetyl-
Fucose (Millipore Calbiochem, Merck KGaA, Darmstadt, 
Germany) at 64 μM for 72 hours prior to performing 
experiments. To assess effect of 2F-Peracetyl-Fucose on 
orosphere formation, the number and size of orospheres 
were measured. At least 50 spheres for each sample were 
measured, reporting the diameter as mean with 95% 
confidence interval. 2F-Peracetyl-Fucose did not affect 
viability at the concentration used (Supplementary Figure 
3).
Phenotypic characterization and ALDH activity 
assay of orospheres vs adherent cells
For flow cytometry, adherent cells were detached 
with trypsin/versene dissociation medium (Gibco, NY, 
USA). Briefly, the culture medium was discharged, cells 
were washed in PBS, and dissociation medium added and 
kept until cells detached from flasks. For dissociation 
of spheres, spheres were collected by centrifugation, 
washed with PBS (Gibco, NY, USA), and then 1 ml of 
dissociation medium added until the orospheres were 
completely dissociated. Cells were re-suspended at 1x106/
ml and incubated with primary antibody for 30 minutes 
on ice in the dark. Secondary antibodies, when needed, 
were added after a PBS wash for 30 minutes in the same 
conditions. Primary antibodies were PE-CD24, PE/Cy5-
CD29, FITC-CD56 (N-CAM), not conjugated CD15s 
(SleX, mouse IgM), and APC-CD44 (BD, CA, USA). SLa 
(sialyl Lewis A, mouse IgG) and Ly (Lewis Y, mouse IgM) 
were not conjugated (Abcam, Cambridge, UK). Alexa488-
conjugated secondary anti-mouse IgM and IgG antibodies 
were purchased from Life Technologies (NY, USA). 
The Aldefluor kit (STEMCELL Technologies, 
BC, Canada) was used to identify cell populations 
with high aldehyde dehydrogenase (ALDH) activity. 
Briefly, 106 harvested cells were resuspended in 
Aldefluor assay buffer containing ALDH substrate, as 
recommended by the producer. As a negative control for 
all samples, an aliquot of “Aldefluor-exposed” cells was 
immediately quenched with a specific ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB). After incubation for 
30 min at 4°C and following centrifugation, the cells were 
resuspended in cold Aldefluor buffer, and stained with 1 
µg/ml propidium iodide (PI) (Sigma Aldrich, MO, USA) 
to discriminate viable from dead cells. Aldefluor staining 
was detected in a green fluorescence channel. Samples 
treated with the inhibitor DEAB (+DEAB) were used as 
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controls to set the gates defining the ALDH+ region. Flow 
cytometry analyses and sorting were performed at the 
University of Michigan Flow Core using a FACS ARIA 
III (Becton Dickinson), a MoFlow Astrios (Beckman 
Coulter, Inc), a FACS Canto III (Becton Dickinson), or a 
MacsQuant (Miltenyi Biotec). All data were analyzed by 
Flow-Jo software (Tree Star, Inc).
RNA isolation, qRT-PCR, and PCR arrays
Total RNA was isolated by using TRIzol 
(Invitrogen, NY, USA). RNA (2 µg) was reverse 
transcribed with TaqMan reverse transcription reagents 
(Applied Biosystems, Branchbury, NJ, USA), following 
the manufacturer’s recommendations. The resulting 
cDNA was then amplified by real time RT-PCR (qRT-
PCR) using AmpliTaq Gold DNA Polymerase (Applied 
Biosystems). The RT-PCR products were subcloned 
into pGEM-T Easy vector (Promega, Madison, WI) and 
confirmed by sequencing. For RNA quantification, qRT-
PCR amplifications were performed at 95°C for 30 s, 
60°C for 30 s, and 72°C for 30 s using specific primers for 
the house-keeping gene β-actin (Actb). The PCR primers 
sequences are given in Supplementary Table 1. The 
relative expression levels for each gene were calculated 
based on the expression levels of Actb and the differences 
are presented in graphs using the 2-ΔΔCT method. 
P-values were calculated using two-sample t-test.
PCR arrays were purchased from Qiagen (QIAGEN, 
Valencia, CA). The arrays and data analyses were 
performed at University of Michigan’s DNA core.
Xenograft formation in NOD/SCID mice
Adherent cells and orospheres were enzymatically 
dissociated to obtain single-cell suspensions, diluted to 
5x104/50μl in PBS, mixed with 50 µl of Matrigel (Becton 
Dickinson, CA, USA), and injected subcutaneously 
in 6-week-old female NOD/SCID mice (Harlan Italy, 
Milan, Italy). Each mouse received an adherent cell 
injection in the left flank and a spheroid-cell injection 
in the right flank. Mice were monitored every 3 days for 
the appearance of subcutaneous tumors. Tumor size was 
measured weekly with calipers. Tumor volume (V) was 
calculated as follows: V = W2×L×0.5, where W and L 
were tumor width and length, respectively. After 45 days, 
mice were sacrificed, and the tumor tissue was collected 
and fixed in buffered formalin. Hematoxylin and eosin 
(H&E) stain was performed to determine tumor histology. 
All procedures and experiments involving animals were 
approved and conducted according to the regulations of 
the Animal Ethic Committee of the Second University of 
Naples.
In vitro treatment with cisplatin 
Cisplatin (cis-diammineplatinum (II) dischloride, 
DDP) (Sigma-Aldrich, St. Louis, MO, USA) was dissolved 
in sterile 0.9% NaCl to achieve a stock concentration of 
5 mM. Cells were plated 3–5x105 in 25cm2 flasks, left to 
grow for 24 hours, and then treated. To establish cisplatin 
dosage for further experiments, cytotoxic curves were 
performed with Annexin V/PI staining kit on adherent 
cells at the concentrations of 2 µM, 5 µM, 20 µM, 40 µM, 
80µM, and 100µM for 24 hours (Supplementary Figure 1). 
The cisplatin dose was chosen in order to produce at least 
20% reduction in viability. Cells were then treated with 
cisplatin 80µM for 24 hours in the subsequent experiment. 
In vitro treatment with radiation
Cells are irradiated at the Experimental Irradiation 
Core of the Comprehensive Cancer Center, University 
of Michigan. 250kV X-ray radiation (Philips RT250, 
Kimtron Medical) was delivered at a dose rate of 
approximately 2 Gy/min. Dosimetry was carried out with 
an electrometer system directly traceable to a National 
Institute of Standards and Technology calibration. Both 
cell lines considered were given 6 Gy.
IC50 calculation and MTT assay
In order to calculate IC50, a dose-response curve 
was obtained by treating both cell lines with cisplatin, 
either in adherent or sphere culture conditions. Cells were 
plated at 1×104 per well in 96-well plates before treatment 
with the following concentrations of cisplatin: 2 µM, 5 
µM, 20 µM, 40 µM, 80µM, 120 µM, and 180 µM. After 
24 h of treatment, MTT solution (1 mg/mL in PBS) was 
added to each well. The plates were then incubated at 
37 °C for 4 h, and reduced purple-blue MTT formazan 
crystals were solubilized by adding 200 μL of DMSO to 
each well. The absorbance was measured at 595 nm using 
a microplate ELISA reader, with DMSO used as the blank. 
IC50 was calculated using Prism GraphPad Sofware 
(GraphPad Software, La Jolla, CA USA).
Colony Forming Assay 
Orospheres and adherent cells received either 80 µM 
cisplatin for 24 hours or 6 Gy. Cells were then washed 
twice with PBS, adherent cell detached, and orospheres 
disaggregated using trypsin/EDTA for 5 minutes. Cells 
were then seeded at 250/cm2. Untreated cells for both 
adherent cultures and orospheres were used as control 
and to assess plating efficiency. Cultures were observed 
for 7–14 days (depending on growth rate differences 
between cell lines) to allow untreated cells to reach >50 
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cells/colony. Colonies were then fixed and stained with 
crystal violet in 20% methanol. Plating efficiency (PE) 
was calculated by dividing the number of colonies formed 
in the no treatment group by the number of cells seeded 
(PE=# of colonies formed/# of cells seeded). Survival 
fraction (SF) was determined by colonies formed after 
treatment divided by the number of cells seeded multiplied 
by the plating efficiency (SF=# colonies formed/# of cells 
seeded x PE). All experiments were done in triplicate.
Shear flow assay
Regular and E-selectin stably transfected Chinese 
Hamster Ovarian cells (CHO and E-sel-CHO cells were 
a gift from Dr Lloyd Stoolman, Pathology Department, 
University of Michigan), that grow as monolayers in 
culture, were maintained in MEM-α media (20% FBS, 
1X NEAA, 1X pen-strep). CHO cells were counted using 
a Beckman Coulter Counter and then incubated with the 
fluorescent marker CFSE (5-(and -6)-carboxyfluorescein 
diacetate succinimidyl ester) diluted with PBS (25 μM) 
for 30 minutes. The cells were then centrifuged for 5 
minutes at 1300 rpm, re-suspended at 1 x 106 cell/ml 
and incubated for 30 minutes in DMEM media (10% 
FBS, 1X NEAA, 1X pen-strep). The tumor cells were 
perfused over the CHO monolayer at 1.4 dynes/cm2 using 
a Harvard Apparatus. The shear force was calculated using 
the equation y=6Qµ/bh2, where y is the shear force in 
dynes/cm2, Q is the flow rate in mL/sec, µ is the apparent 
viscosity (which is 0.01 poise for water at 32°C), and b 
is the width and h is the height of the gasket. A gasket 
with dimensions of 0.005 cm in height and 0.25 cm wide 
was used. A computer software program, SIMPLE40, was 
employed to analyze the recorded video in conjunction 
with a standard CCD camera. Two-minute segments of the 
videos were analyzed at various time points and positions 
throughout the flow adhesion assay. An average was taken 
of the total number of cells that were either considered 
rolling or sticking to the monolayer, so that a value of 
cells per field was obtained and compared. ‘Rolling’ cells 
were considered to have velocities from 1.2–100 μm/s; 
‘sticking’ cells had velocities of 0–1.2 μm/s.
Invasion Assay
The invasion assays were performed using BD 
BioCoat Matrigel Invasion Chamber and BD control 
inserts (Becton-Dickinson, MA). The cells, as orospheres 
and sorted for SLex expression by flow cytometry, were 
re-suspended in serum-free DMEM and then added onto 
inserts with uncoated filter (control inserts) or onto inserts 
with Matrigel coated filters (Invasion chambers) at the 
density of 5×104 cells/insert. DMEM containing 10% 
FBS was used as the chemoattractant. After incubation 
of 22 hours at 37°C, 5% CO2, non-invading cells on the 
upper side of the membrane were removed with cotton 
swabs and the invading cells were fixed using methanol 
and stained with hematoxylin. Cells that invaded were 
counted at 200X magnification. Each assay was performed 
in triplicate. Invasion was calculated as percentage of cells 
that invaded the Matrigel insert compared to the number of 
cells that migrate in the control insert. 
Statistical analysis
Statistical analyses were carried out by University 
of Michigan Center for Statistical Consultation and 
Research (CSCAR). An Independent Samples test was run 
using the SPSS program to analyze the significance of the 
differences found. P-values less than 0.05 were considered 
to be statistically significant. In all graphs, error bars 
represent the 95% confidence interval.
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